| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Technical Briefs |
1 Department of Clinical Chemistry, George-August University Goettingen, 37075 Goettingen, Germany
aaddress correspondence to this author at: Abteilung Klinische Chemie, Zentrum Innere Medizin, Georg-August-Universität Göttingen, Robert-Koch-Strasse 40, 37075 Göttingen; fax 49-551-398551, e-mail varmstro@med.uni-goettingen.de
With the introduction of the novel immunosuppressive agents sirolimus and everolimus, new, potentially more effective immunosuppressive regimens are undergoing clinical evaluation. Whereas the calcineurin inhibitors cyclosporin A (CsA) and tacrolimus suppress early activation of T lymphocytes through inhibition of cytokines such as interleukin 2, the primary target of sirolimus and everolimus is mammalian target of rapamycin (mTOR), a specific cell-cycle regulatory protein. The inhibition of mTOR leads to suppression of cytokine-driven T-lymphocyte proliferation (1). Because of their distinct modes of action, a calcineurin inhibitor and an mTOR inhibitor act synergistically to block acute allograft rejection (2)(3)(4). Current evidence (5) suggests that drug monitoring is necessary, not only for the calcineurin inhibitors, but also for the mTOR inhibitors. In contrast to the calcineurin inhibitors, however, there are currently no commercially available immunoassays for the latter two drugs. There is a need, therefore, for assays that can simultaneously quantify both the calcineurin and the mTOR inhibitors. Furthermore, a major shortcoming of the commercial immunoassays for CsA and tacrolimus is their cross-reactivity with unpredictable amounts of both active and inactive metabolites of the parent drugs in patient samples. In the case of CsA, no immunoassay has completely fulfilled the criteria recommended by a consensus panel (6).
New developments in immunosuppression protocols require that assays for calcineurin inhibitors provide broader dynamic ranges. On the one hand, C2 monitoring has been proposed for optimizing dosage of the CsA microemulsion (7), thereby necessitating quantification of CsA at concentrations up to 2500 µg/L: the lack of validated dilution protocols can be a problem for C2 monitoring (8). On the other hand, lower target ranges for CsA (5) and tacrolimus (9) are being investigated for long-term maintenance therapy
Acknowledgments
References
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  S. Kramer, Y. Wang-Rosenke, V. Scholl, E. Binder, T. Loof, D. Khadzhynov, H. Kawachi, F. Shimizu, F. Diekmann, K. Budde, et al. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat Am J Physiol Renal Physiol, February 1, 2008; 294(2): F440 - F449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Annesley Methanol-Associated Matrix Effects in Electrospray Ionization Tandem Mass Spectrometry Clin. Chem., October 1, 2007; 53(10): 1827 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Napoli Organic solvents compromise performance of internal standard (ascomycin) in proficiency testing of mass spectrometry-based assays for tacrolimus. Clin. Chem., April 1, 2006; 52(4): 765 - 766. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Anderson and C. L. Hunter Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins Mol. Cell. Proteomics, April 1, 2006; 5(4): 573 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Taylor, S. R. Brown, D. P. Cooper, P. Salm, M. R. Morris, P. I. Pillans, and S. V. Lynch Evaluation of 3 Internal Standards for the Measurement of Cyclosporin by HPLC-Mass Spectrometry Clin. Chem., October 1, 2005; 51(10): 1890 - 1893. [Full Text] [PDF]
|
|
|
|
|
|
G. Khoschsorur Simultaneous Measurement of Sirolimus and Everolimus in Whole Blood by HPLC with Ultraviolet Detection Clin. Chem., September 1, 2005; 51(9): 1721 - 1724. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Anderson Candidate-based proteomics in the search for biomarkers of cardiovascular disease J. Physiol., February 15, 2005; 563(1): 23 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Annesley Application of Commercial Calibrators for the Analysis of Immunosuppressant Drugs in Whole Blood Clin. Chem., February 1, 2005; 51(2): 457 - 460. [Full Text] [PDF]
|
|
|
|
|
|
T. M. Annesley and L. Clayton Simple Extraction Protocol for Analysis of Immunosuppressant Drugs in Whole Blood Clin. Chem., October 1, 2004; 50(10): 1845 - 1848. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Juenke, P. I. Brown, F. M. Urry, and G. A. McMillin Specimen Dilution for C2 Monitoring with the Abbott TDxFLx Cyclosporine Monoclonal Whole Blood Assay Clin. Chem., August 1, 2004; 50(8): 1430 - 1433. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
